Who
Robert L. Zerbe
Director
Company insider
Files Form 4 as: Director, Vericel; Director, Optimer Pharmaceuticals; Director, Heron Therapeutics; Director, Anesiva; Director, Maxim Pharmaceuticals.
In numbers
- Trades disclosed
- 124
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $1.9M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 4 Jan 2006
- Last trade
- 29 Apr 2026
- Last filed
- 1 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Apr 2026filed 1 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 5 Feb 2025filed 7 Feb 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $33K2,500 at $13.05 | filing |
| 5 Feb 2025filed 7 Feb 2025 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $156K2,500 at $62.50 | filing |
| 22 Nov 2024filed 25 Nov 2024 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 22 Nov 2024filed 25 Nov 2024 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $33K2,500 at $13.05 | filing |
| 22 Nov 2024filed 25 Nov 2024 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $150K2,500 at $60.00 | filing |
| 12 Nov 2024filed 13 Nov 2024 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 12 Nov 2024filed 13 Nov 2024 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $33K2,500 at $13.05 | filing |
News
No headline names them, or the companies they trade most, lately.